MedCap (MCAP) Company presentation summary

Business overview and strategy

• Focuses on life science with three main business areas: Assistive Tech, MedTech, and Specialty Pharma.

• Operates a buy & build strategy, acquiring and scaling small to mid-sized companies in Europe.

• Emphasizes decentralized management, local responsibility, and long-term value creation.

• Targets companies with strong value propositions, proven profitability, and scalable business models.

• Maintains active ownership and leverages a network of expertise for knowledge sharing and market insight.

Financial performance and targets

• Achieved SEK 1,807 million in revenue for 2024, with a 23% EBITA CAGR over five years.

• EBITA margin stands at 17%, with a return on equity target above 20%.

• Net debt to EBITDA ratio is kept below 3x, supporting financial stability.

• Sales CAGR over five years is 19%, reflecting consistent growth.

• Financial objectives include >15% annual EBITA growth and ongoing business expansion through organic and acquisition-driven sales.

Market positioning and growth drivers

• Operates in non-cyclical, demographically driven markets with significant niche and market share potential.

• Portfolio companies contribute to inclusion, care, and healthcare, aligning with UN sustainable development goals.

• Market trends include digitalization, telemedicine, aging population, and increased prevalence of chronic conditions.

• Large, fragmented European market offers strong acquisition opportunities.

• Business areas address consumer health, diagnostics, and pharmaceutical shortages.